As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|May 22, 2018
Pharma’s Data Tsunami Problem
Author(s)Michelle Maskaly
William Carson, president & CEO of Otsuka Pharmaceutical’s development and commercialization, talks about the challenges facing the pharmaceutical industry when it comes to the massive amounts of data being collected.
Advertisement
William Carson, president & CEO of Otsuka Pharmaceutical’s development and commercialization, talks about the challenges facing the pharmaceutical industry when it comes to the massive amounts of data digital medicines, and other devices, are collecting. His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.
Advertisement
Related to this article
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5